Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance ...

JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares closed last Friday at $19.70. See what stocks are ...

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report)’s stock price rose 6.6% during trading on Friday after the company announced better than expected quarterly earnings. The company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $56.3 million in its fourth quarter. The Waltham, Massachusetts-based company said it ...

Finally, Robert W. Baird boosted their price objective on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th.